DNA Genotek's Gut
Microbiome Grant Program
DNA Genotek's
Grant Program
GenoFIND Genomic
Services Award
DNA Genotek's
Your Choice Award
Direct Line:
+1 (613) 723-5757

"The collection protocol is very convenient, the extraction is very quick and simple, and the yield is great. Our downstream applications include PCR, restriction enzyme digestion and sequencing. We have collected numerous family members who were not willing to go for a blood draw, as well as children, elderly patients and overseas relatives. The ease of shipping and self-collection are remarkable. Our lab is very impressed with this timely product."

Ruth McPherson, MD, PhD
Nihan Kavaslar, PhD
Lipoproteins and Atherosclerosis Research Group
University of Ottawa Heart Institute

We are pleased to announce the recipients of the DNA Genotek Grant Program to you today. The quality of the applications we received exceeded our expectations and the selection committee had a difficult task to review and evaluate each proposal carefully before selecting the winners. We originally planned to award only one grant but the quality and quantity of applications we received has resulted in two winning proposals. The recipients are:

Who: Dr. Paul Arnold
Position: Principal Investigator
Institution: The Hospital for Sick Children, Toronto, Canada

Abstract: DNA Methylation Profiles of Saliva in Paediatric Obsessive Compulsive Disorder (OCD).

Obsessive-Compulsive Disorder (OCD), a common and debilitating neuropsychiatric disorder, is highly heritable. However, few genetic risk factors have been identified for OCD. We propose a novel approach in which we study DNA methylation, a type of chemical modification of DNA which has been shown to influence development of other disorders and which can potentially be modified by environmental factors. We will use a highly accessible tissue (saliva) to identify epigenetic changes which will be potentially useful for personalized treatment. Personalized medicine has the potential to be highly beneficial to OCD sufferers since medications are effective in only 50 to 60% of cases and adverse effects often lead to discontinuation of treatment.

Who: Dr. David J. Speicher
Position: Principal Investigator
Institution: Griffith Health Institute, Queensland, Australia

Abstract: Salivary Diagnostics of HIV, HHV-8 and HPV in two distinct HIV-positive populations: Port Moresby, Papua New Guinea and Chennai, India.

Early diagnosis of HIV infection and institution of treatment is essential to prevent opportunistic viral infections, such as Kaposi's sarcoma (KS) caused by HHV-8 and head & neck cancers caused by oncogenic HPV. Saliva, whole mouth fluid and blood will be collected from 384 and 185 HIV-positive HAART patients in PNG and India. The viral loads of human herpesvirus 8 (HHV-8), human papillomavirus (HPV), and human immunodeficiency virus (HIV) will be compared between saliva and traditional whole mouth fluid collection methods using frozen saliva, and blood.

Dr. Arnold will be awarded $30,000(US) along with 260 Oragene®•DNA collection kits while Dr. Speicher will be awarded $25,000(US) and 400 OMNIgene®•DISCOVER collection kits. Please join us in congratulating these two outstanding researchers. We wish we could have awarded more grants as we reviewed so many worthy applications. Thank you to everyone who applied for the DNA Genotek Grant Program and we wish you the best of luck with your research projects.

Rewarding scientists who are fostering innovative research into the genetic basis of cancer, personalized medicine, and infectious disease.

The DNA Genotek Grant Program is designed to foster innovative and novel proposals for the use of DNA Genotek products in the research of the genetic/genomic basis of one of the following*:

  • Cancer
  • Personalized medicine
  • Infectious disease

*Notable proposals for the use of DNA Genotek products in research focused on other disease(s) are also encouraged.

The Grant Program will reward scientists who are using DNA Genotek products to accelerate the advancement of genetics to gain knowledge to address problems in the 3 identified fields of research. The successful proposal will enhance the understanding of how the genetic/genomic basis of disease contributes to the development of new therapeutic approaches.

Eligible researchers should complete the Grant Program application and submit this to DNA Genotek by midnight, ET (GMT -5) on January 16, 2012.

Application deadline: midnight ET (GMT -5) on January 16, 2012

Award amount: (up to) $30,000 US and (up to) 500 DNA Genotek biological sample collection kits to facilitate collection of DNA or RNA for use in the execution of the winning proposal (exact product and format to be determined in conjunction with the winner)

Winner announced: NEW DATE: March 27, 2012 on www.dnagenotek.com/US/grant

Program Rules

  1. One entry per investigative team. Investigators in all countries are eligible.
  2. All submitted materials must be in English.
  3. Applicants who have a relative or member of their household currently employed by DNA Genotek are ineligible to enter.
  4. Applicant is responsible for ensuring that all necessary and legally required informed consents, authorizations, approvals, and permissions have been obtained in order to participate in this program, including any required Internal Review Board (IRB) approvals.
  5. Applicant agrees that the project will be complete within 1 year of the date of the award being received, if selected as the winner.
  6. Applicants must agree to DNA Genotek's product terms and conditions applicable to the 500 (maximum) biological sample collection kits.
  7. Applicants must allow DNA Genotek to publicly announce their name, project name or area of research, and institution or company if they are selected as a winner.
  8. DNA Genotek will keep all abstracts, applicant names and institutions, and all information submitted in the program application confidential, except in the case of the winner.
  9. All decisions of the selection committee are final. The selection process is confidential.
  10. The winner agrees to provide a written progress report on the project to DNA Genotek six months after the receipt of the award.
  11. The winner agrees that within 30 days of the completion date of the project, they will submit a written financial report outlining the use of award funds as well as a written report on all findings, data, results, and information as a result of the project.
  12. The winner agrees to present the data and/or milestones of the project at an ancillary session at the ASHG Annual Meeting. DNA Genotek will pay the travel and living costs for the winner (one person) to present at ASHG.
  13. Applications will only be accepted for consideration if sent to DNA Genotek via the online application form. All other applications will be rejected and destroyed. Under no circumstances will any materials be returned.
  14. Applicants agree to comply with the Additional Grant Program Terms and Conditions.

If you have any questions about the DNA Genotek Grant Program, please email grants@dnagenotek.com


© 2018 DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc., all rights reserved.     Support | Contact Us | Quality | Privacy Policy | Accessibility Policy | Legal Notices | Web Feedback